Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.61 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22798219 | 1.00 | CAPN1 (0.61) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL18619560 | 1.00 | CAPN1 (0.61) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL22798286 | 1.00 | CAPN1 (0.61) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL18620610 | 0.92 | CAPN1 (0.59) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL22209493 | 0.92 | CAPN1 (0.59) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL9415824 | 0.89 | CAPN1 (0.57) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL22364699 | 0.88 | CAPN1 (0.54) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL30896685 | 0.84 | CAPN1 (0.53) | CAPN1CTSKCTSBCTSL | |
| SCHEMBL1506251 | 0.82 | ACE (0.61) | CAPN1CTSKCTSBCTSLCCR1 | |
| SCHEMBL10063674 | 0.82 | ACE (0.61) | CAPN1CTSKCTSBCTSLCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | CAPN1 763/4885CTSK 1748/4885CTSB 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.